Pfizer shares rise; EMA CHMP issues positive opinion on HYMPAVZI label expansion for hemophilia A or B patients 12+ with inhibitors

Pfizer Inc. -0.86%

Pfizer Inc.

PFE

26.57

-0.86%

  • EMA’s CHMP issued a positive opinion for Pfizer’s HYMPAVZI (marstacimab) to expand EU use to patients age 12+ and weighing at least 35 kg with hemophilia A or B with inhibitors.
  • The European Commission is reviewing the CHMP recommendation and is expected to issue a final decision in the coming months.
  • The FDA accepted Pfizer’s supplemental Biologics License Application for HYMPAVZI and granted Priority Review to expand routine prophylaxis to hemophilia A or B patients age 6+ with or without inhibitors.
  • The FDA set a PDUFA action date in Q2 2026.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Pfizer Inc. published the original content used to generate this news brief on March 27, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.